 |
PDBsum entry 1k5k
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Transcription
|
PDB id
|
|
|
|
1k5k
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
Contents |
 |
|
|
|
|
|
|
|
|
* Residue conservation analysis
|
|
|
|
|
|
PDB id:
|
|
|
|
| Name: |
|
Transcription
|
|
|
Title:
|
|
Homonuclear 1h nuclear magnetic resonance assignment and structural characterization of HIV-1 tat mal protein
|
|
Structure:
|
|
Tat protein. Chain: a. Synonym: transactivating regulatory protein. Engineered: yes
|
|
Source:
|
|
Synthetic: yes. Other_details: the protein was chemically synthesized. The sequence of the protein is naturally found in human immunodeficiency virus-1.
|
|
NMR struc:
|
|
10 models
|
|
|
Authors:
|
|
C.Gregoire,J.M.Peloponese,D.Esquieu,S.Opi,G.Campbell,M.Solomiac, E.Lebrun,J.Lebreton,E.P.Loret
|
|
Key ref:
|
|
C.Grégoire
et al.
(2001).
Homonuclear (1)H-NMR assignment and structural characterization of human immunodeficiency virus type 1 Tat Mal protein.
Biopolymers,
62,
324-335.
PubMed id:
|
|
|
Date:
|
|
|
11-Oct-01
|
Release date:
|
19-Jun-02
|
|
|
|
|
|
|
PROCHECK
|
|
|
|
|
|
Headers
|
|
|
|
References
|
|
|
|
|
|
|
|
P04613
(TAT_HV1MA) -
Protein Tat from Human immunodeficiency virus type 1 group M subtype A (isolate MAL)
|
|
|
|
Seq:
Struc:
|
|
|
|
87 a.a.
87 a.a.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Key: |
 |
PfamA domain |
|
|
 |
Secondary structure |
|
 |
CATH domain |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
| |
|
|
Biopolymers
62:324-335
(2001)
|
|
PubMed id:
|
|
|
|
|
|
| |
|
Homonuclear (1)H-NMR assignment and structural characterization of human immunodeficiency virus type 1 Tat Mal protein.
|
|
C.Grégoire,
J.M.Péloponèse,
D.Esquieu,
S.Opi,
G.Campbell,
M.Solomiac,
E.Lebrun,
J.Lebreton,
E.P.Loret.
|
|
|
|
|
| |
ABSTRACT
|
|
|
|
| |
|
|
The transacting transcriptional activator (Tat) is a viral protein essential for
activation of the human immunodeficiency virus (HIV) genes, and it plays an
important role in HIV induced immunodeficiency. We report the NMR structural
characterization of the active Tat Mal variant that belongs to a highly virulent
D-subtype HIV type-1 (HIV-1) strain (Mal) found mainly in Africa. A full Tat Mal
protein (87 residues) is synthesized. This synthetic protein is active in a
transactivation assay with HeLa cells infected with the HIV long terminal
repeated noncoding sequences of the HIV-1 provirus (LTR) lac Z gene. Homonuclear
(1)H-NMR spectra allows the sequential assignment of the Tat Mal spin systems.
Simulating annealing generates 20 conformers with similar folding. The geometry
of the mean structure is optimized with energy minimization to obtain a final
structure. As the European variant (Tat Bru) the N-terminal region of Tat Mal
constitutes the core, and there is a hydrophobic pocket composed of the
conserved Trp 11 interacting with several aromatic residues. The two functional
regions of Tat (basic and the cysteine-rich regions) are well exposed to the
solvent. A short alpha-helix is observed in region V adjacent to the basic
region. This alpha helix induces local structural variations compared to the NMR
structure of Tat Bru, and it brings the cysteine-rich and basic regions closer.
This study suggests that similar folding exists among Tat variants.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
 |
 |
|
Literature references that cite this PDB file's key reference
|
|
|
| |
PubMed id
|
|
Reference
|
|
|
|
|
|
M.K.Johri,
R.Mishra,
C.Chhatbar,
S.K.Unni,
and
S.K.Singh
(2011).
Tits and bits of HIV Tat protein.
|
| |
Expert Opin Biol Ther,
11,
269-283.
|
|
|
|
|
|
|
A.Caputo,
R.Gavioli,
S.Bellino,
O.Longo,
A.Tripiciano,
V.Francavilla,
C.Sgadari,
G.Paniccia,
F.Titti,
A.Cafaro,
F.Ferrantelli,
P.Monini,
F.Ensoli,
and
B.Ensoli
(2009).
HIV-1 Tat-based vaccines: an overview and perspectives in the field of HIV/AIDS vaccine development.
|
| |
Int Rev Immunol,
28,
285-334.
|
|
|
|
|
|
|
G.R.Campbell,
and
E.P.Loret
(2009).
What does the structure-function relationship of the HIV-1 Tat protein teach us about developing an AIDS vaccine?
|
| |
Retrovirology,
6,
50.
|
|
|
|
|
|
|
W.Li,
G.Li,
J.Steiner,
and
A.Nath
(2009).
Role of Tat Protein in HIV Neuropathogenesis.
|
| |
Neurotox Res,
16,
205-220.
|
|
|
|
|
|
|
C.Egelé,
P.Barbier,
P.Didier,
E.Piémont,
D.Allegro,
O.Chaloin,
S.Muller,
V.Peyrot,
and
Y.Mély
(2008).
Modulation of microtubule assembly by the HIV-1 Tat protein is strongly dependent on zinc binding to Tat.
|
| |
Retrovirology,
5,
62.
|
|
|
|
|
|
|
J.D.Watkins,
G.R.Campbell,
H.Halimi,
and
E.P.Loret
(2008).
Homonuclear 1H NMR and circular dichroism study of the HIV-1 Tat Eli variant.
|
| |
Retrovirology,
5,
83.
|
|
|
|
|
|
|
M.Mishra,
S.Vetrivel,
N.B.Siddappa,
U.Ranga,
and
P.Seth
(2008).
Clade-specific differences in neurotoxicity of human immunodeficiency virus-1 B and C Tat of human neurons: significance of dicysteine C30C31 motif.
|
| |
Ann Neurol,
63,
366-376.
|
|
|
|
|
|
|
J.D.Watkins,
S.Lancelot,
G.R.Campbell,
D.Esquieu,
J.de Mareuil,
S.Opi,
S.Annappa,
J.P.Salles,
and
E.P.Loret
(2006).
Reservoir cells no longer detectable after a heterologous SHIV challenge with the synthetic HIV-1 Tat Oyi vaccine.
|
| |
Retrovirology,
3,
8.
|
|
|
|
|
|
|
S.Shojania,
and
J.D.O'Neil
(2006).
HIV-1 Tat is a natively unfolded protein: the solution conformation and dynamics of reduced HIV-1 Tat-(1-72) by NMR spectroscopy.
|
| |
J Biol Chem,
281,
8347-8356.
|
|
|
|
|
|
|
S.Pantano,
and
P.Carloni
(2005).
Comparative analysis of HIV-1 Tat variants.
|
| |
Proteins,
58,
638-643.
|
|
|
|
|
|
|
G.R.Campbell,
E.Pasquier,
J.Watkins,
V.Bourgarel-Rey,
V.Peyrot,
D.Esquieu,
P.Barbier,
J.de Mareuil,
D.Braguer,
P.Kaleebu,
D.L.Yirrell,
and
E.P.Loret
(2004).
The glutamine-rich region of the HIV-1 Tat protein is involved in T-cell apoptosis.
|
| |
J Biol Chem,
279,
48197-48204.
|
|
|
|
|
|
|
S.Misumi,
N.Takamune,
Y.Ohtsubo,
K.Waniguchi,
and
S.Shoji
(2004).
Zn2+ binding to cysteine-rich domain of extracellular human immunodeficiency virus type 1 Tat protein is associated with Tat protein-induced apoptosis.
|
| |
AIDS Res Hum Retroviruses,
20,
297-304.
|
|
|
|
|
|
|
T.J.Ruckwardt,
I.Tikhonov,
S.Berg,
G.S.Hatfield,
A.Chandra,
P.Chandra,
B.Gilliam,
R.R.Redfield,
R.C.Gallo,
and
C.D.Pauza
(2004).
Sequence variation within the dominant amino terminus epitope affects antibody binding and neutralization of human immunodeficiency virus type 1 Tat protein.
|
| |
J Virol,
78,
13190-13196.
|
|
|
|
|
|
|
I.Tikhonov,
T.J.Ruckwardt,
G.S.Hatfield,
and
C.D.Pauza
(2003).
Tat-neutralizing antibodies in vaccinated macaques.
|
| |
J Virol,
77,
3157-3166.
|
|
|
|
|
|
|
S.Opi,
J.M.Péloponèse,
D.Esquieu,
G.Campbell,
J.de Mareuil,
A.Walburger,
M.Solomiac,
C.Grégoire,
E.Bouveret,
D.L.Yirrell,
and
E.P.Loret
(2002).
Tat HIV-1 primary and tertiary structures critical to immune response against non-homologous variants.
|
| |
J Biol Chem,
277,
35915-35919.
|
|
|
|
|
|
The most recent references are shown first.
Citation data come partly from CiteXplore and partly
from an automated harvesting procedure. Note that this is likely to be
only a partial list as not all journals are covered by
either method. However, we are continually building up the citation data
so more and more references will be included with time.
|
|
Links
